

23

Sheet 1 of 3

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1256R3

Serial No.

09/209,023

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Paton et al.

Filing Date

10 Dec 1998

Group

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ALH	65	4,753,894	28.06.88	Frankel et al.			
	66	4,935,341	19.06.90	Bargmann et al.			
	67	4,943,533	24.07.90	Mendelsohn et al.			
	68	4,968,603	06.11.90	Slamon et al.			
	69	4,975,278	04.12.90	Senter et al.			
	70	5,169,774	08.12.92	Frankel et al.			
	71	5,183,884	02.02.93	Kraus et al.			
	72	5,288,477	22.02.94	Bacus, S.			
	73	5,367,060	22.11.94	Vandlen et al.			
	74	5,401,638	28.03.95	Carney et al.			
	75	5,464,751	07.11.95	Greene et al.			
	76	5,480,968	02.01.96	Kraus et al.			
	77	5,604,107	18.02.97	Carney et al.			
	78	5,641,869	24.06.97	Vandlen et al.			
	79	5,663,144	02.09.97	Greene et al.			
	80	5,720,937	24.02.98	Hudziak et al.			
	81	5,720,954	24.02.98	Hudziak et al.			
	82	5,725,856	10.03.98	Hudziak et al.			
	83	5,726,023	10.03.98	Cheever et al.			
	84	5,747,261	05.05.98	King et al.			
	85	5,770,195	23.06.98	Hudziak et al.			
	86	5,772,997	30.06.98	Hudziak et al.			
	87	5,776,427	07.07.98	Thorpe et al.			
	88	5,801,005	01.09.98	Cheever et al.			
	89	5,821,337	13.10.98	Carter et al.			
	90	5,824,311	20.10.98	Greene et al.			
	91	5,834,229	10.11.98	Vandlen et al.			
	92	5,837,243	17.11.98	Deo et al.			
	93	5,837,523	17.11.98	Greene et al.			
	94	5,840,525	24.11.98	Vandlen et al.			
	95	5,846,538	08.12.98	Cheever et al.			
	96	5,856,110	05.01.99	Vandlen et al.			
	97	5,859,206	12.01.99	Vandlen et al.			
	98	5,869,445	09.02.99	Cheever et al.			
	99	5,876,712	02.03.99	Cheever et al.			
	100	5,877,305	02.03.99	Huston et al.			

RECEIVED

JUN 03 2002

TECH CENTER 1600/2900

Examiner

Anne L. Halleran

Date Considered

2/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1256R3

Serial No.

09/209,023

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Paton et al.

Filing Date

10 Dec 1998

Group

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
Ault ↓ V	101	5,910,486	08.06.99	Curriel et al.			
	102	5,922,845	13.07.99	Deo et al.			
	103	5,939,531	17.08.99	Wels et al.			
	104	5,977,322	02.11.99	Marks et al.			
	105	5,985,553	16.11.99	King et al.			
	106	6,015,567	18.01.00	Hudziak et al.			
	107	6,028,059	22.02.00	Curriel et al.			
	108	6,054,297	25.04.00	Carter et al.			
	109	6,054,561	25.04.00	Ring, D. B.			
	110	6,123,939	26.09.00	Shawver et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
Ault Ault	111	0,599,274 A1	01.06.94	EPO				
	112	0,711,565 B1	26.08.98	EPO				
	113	2,895,105 B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	114	95,006,982 B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	115	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	116	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	117	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	118	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	119	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	120	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)				
	121	2,761,543 B2	04.06.98	JAPAN (TRANSLATION ATTACHED)				
	122	WO 92/10573	25.06.92	PCT				
	123	WO 93/12220	24.06.93	PCT				
	124	WO 93/21232	28.10.93	PCT				
	125	WO 93/21319	28.10.93	PCT				
	126	WO 94/28127	08.12.94	PCT				
	127	WO 95/16051	15.06.95	PCT				
	128	WO 95/17507	29.06.95	PCT				
	129	WO 95/28485	26.10.95	PCT				
	130	WO 96/18409	20.06.96	PCT				
	131	WO 97/27848	07.08.97	PCT				
	132	WO 97/38731	23.10.97	PCT				
	133	WO 98/17797	30.04.98	PCT				

Examiner

Anne L. Holleran

Date Considered

2/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1256R3

Serial No
09/209,023

Applicant
Paton et al.

Filing Date
10 Dec 1998

Group
1642

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
Alt	134 WO 98/45479	15.10.98	PCT				
Alt	135 WO 99/31140	24.06.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- ✓ 136 Baselga and Mendelsohn, "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" Pharmac. Ther. 64:127-154 (1994)
- ✓ 137 De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" Cancer Research 52:1916-1923 (1992)
- ✓ 138 Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" Proceedings of the American Association for Cancer Research (abstract #3209) 37:470 (Mar 1996)
- ✓ 139 Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" Cancer Research 56:1457-1465 (Mar 15, 1996)
- ✓ 140 Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" Cancer Research 44(3):1002-1007 (Mar 1984)
- ✓ 141 Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" Jpn J. Cancer Res. 80:10-14 (January 1989)
- ✓ 142 McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" Cancer 65(1):88-92 (Jan 1, 1990)
- ✓ 143 Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" J. Cellular Biochem. 35(4):315-320 (1987)
- ✓ 144 Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" Molecular Foundations of Oncology, Broder, S., ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)
- ✓ 145 Slivkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" Proceedings of the American Association for Cancer Research (abstract only) 37:625-626 (Mar 1996)
- ✓ 146 Zhang et al., "Shared antigenic epitopes and pathobiological functions of anti-p185her2/neu monoclonal antibodies" Experimental and Molecular Pathology 67:15-25 (1999)

Examiner

Anne L. Sullivan

Date Considered

2/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC: